John M. Harrold

751 total citations
30 papers, 579 citations indexed

About

John M. Harrold is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John M. Harrold has authored 30 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John M. Harrold's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Neutropenia and Cancer Infections (5 papers) and Glycosylation and Glycoproteins Research (4 papers). John M. Harrold is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Neutropenia and Cancer Infections (5 papers) and Glycosylation and Glycoproteins Research (4 papers). John M. Harrold collaborates with scholars based in United States, Switzerland and Belgium. John M. Harrold's co-authors include Donald E. Mager, Murali Ramanathan, Robert S. Parker, Anson K. Abraham, Yulia Vugmeyster, Xin Xu, T.C. Melewar, Robert M. Straubinger, Leonid Kagan and Juan José Pérez Ruixo and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

John M. Harrold

29 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John M. Harrold United States 15 277 152 139 77 67 30 579
Christophe Meille Switzerland 15 244 0.9× 346 2.3× 82 0.6× 64 0.8× 45 0.7× 30 682
Fumi Kinose United States 17 595 2.1× 265 1.7× 28 0.2× 93 1.2× 47 0.7× 26 857
Rachel M. Webster United States 13 330 1.2× 359 2.4× 105 0.8× 170 2.2× 27 0.4× 29 767
Sophie Callies United States 20 601 2.2× 321 2.1× 41 0.3× 118 1.5× 31 0.5× 44 1.2k
Charlene Kay United Kingdom 16 433 1.6× 443 2.9× 140 1.0× 50 0.6× 34 0.5× 31 954
Anja Henningsson Sweden 8 197 0.7× 567 3.7× 36 0.3× 45 0.6× 23 0.3× 12 889
Brent M. Kuenzi United States 13 524 1.9× 331 2.2× 50 0.4× 85 1.1× 190 2.8× 22 923
Stefania Crucitta Italy 24 727 2.6× 612 4.0× 108 0.8× 133 1.7× 30 0.4× 65 1.5k
Abhik Mukherjee United Kingdom 17 386 1.4× 309 2.0× 41 0.3× 108 1.4× 14 0.2× 41 776
Theresa A. Mays United States 10 773 2.8× 477 3.1× 147 1.1× 126 1.6× 24 0.4× 15 1.2k

Countries citing papers authored by John M. Harrold

Since Specialization
Citations

This map shows the geographic impact of John M. Harrold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Harrold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Harrold more than expected).

Fields of papers citing papers by John M. Harrold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Harrold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Harrold. The network helps show where John M. Harrold may publish in the future.

Co-authorship network of co-authors of John M. Harrold

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Harrold. A scholar is included among the top collaborators of John M. Harrold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Harrold. John M. Harrold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Shufang, et al.. (2024). Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins. Journal of Pharmacokinetics and Pharmacodynamics. 51(5). 449–476. 6 indexed citations
2.
Patilea‐Vrana, Gabriela I., John M. Harrold, Joseph A. Ware, et al.. (2023). Abstract 5668: Using clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD). Cancer Research. 83(7_Supplement). 5668–5668. 2 indexed citations
3.
Pham, Elizabeth, Matthias G. Friedrich, Famke Aeffner, et al.. (2021). Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule. Molecular Cancer Therapeutics. 20(10). 1977–1987. 6 indexed citations
4.
Harrold, John M., Per Olsson, Isabelle Delor, et al.. (2020). Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF. Pharmaceutical Research. 37(6). 102–102. 8 indexed citations
5.
Tiwari, Abhinav, et al.. (2016). Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The AAPS Journal. 19(2). 510–519. 15 indexed citations
6.
Krzyżański, Wojciech, et al.. (2016). A cell-level model of pharmacodynamics-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. 43(5). 513–527. 7 indexed citations
7.
Krzyżański, Wojciech, Juan José Pérez Ruixo, & John M. Harrold. (2015). Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. Journal of Pharmacokinetics and Pharmacodynamics. 42(6). 709–720. 4 indexed citations
8.
Zutshi, Anup, et al.. (2015). Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. Journal of Pharmacokinetics and Pharmacodynamics. 42(1). 1–18. 22 indexed citations
9.
Harrold, John M., Philippe Jacqmin, Per Olsson, et al.. (2014). Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS). Blood. 124(21). 690–690.
10.
Harrold, John M. & Anson K. Abraham. (2014). Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. Journal of Pharmacokinetics and Pharmacodynamics. 41(2). 141–151. 12 indexed citations
11.
Harrold, John M., Murali Ramanathan, & Donald E. Mager. (2013). Network-Based Approaches in Drug Discovery and Early Development. Clinical Pharmacology & Therapeutics. 94(6). 651–658. 75 indexed citations
12.
Harrold, John M., Robert M. Straubinger, & Donald E. Mager. (2012). Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics. Cancer Research. 72(7). 1632–1641. 25 indexed citations
13.
Vugmeyster, Yulia, John M. Harrold, & Xin Xu. (2012). Absorption, Distribution, Metabolism, and Excretion (ADME) Studies of Biotherapeutics for Autoimmune and Inflammatory Conditions. The AAPS Journal. 14(4). 714–727. 38 indexed citations
14.
Vugmeyster, Yulia, Qin Wang, Xin Xu, et al.. (2012). Disposition of Human Recombinant Lubricin in Naive Rats and in a Rat Model of Post-traumatic Arthritis After Intra-articular or Intravenous Administration. The AAPS Journal. 14(1). 97–104. 21 indexed citations
15.
Harrold, John M., Jay Tibbitts, Sandhya Girish, et al.. (2012). Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer. Clinical Pharmacology & Therapeutics. 92(4). 520–527. 45 indexed citations
16.
Kagan, Leonid, Anson K. Abraham, John M. Harrold, & Donald E. Mager. (2010). Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. Pharmaceutical Research. 27(5). 920–932. 40 indexed citations
17.
Zhou, Rong, et al.. (2009). Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model. Journal of Pharmacology and Experimental Therapeutics. 332(2). 479–488. 16 indexed citations
18.
Harrold, John M.. (2005). MODEL-BASED DESIGN OF CANCER CHEMOTHERAPY TREATMENT SCHEDULES. D-Scholarship@Pitt (University of Pittsburgh). 16 indexed citations
19.
Harrold, John M., Julie L. Eiseman, Erin Joseph, et al.. (2005). Control-Relevant Modeling of the Antitumor Effects of 9-Nitrocamptothecin in SCID Mice Bearing HT29 Human Colon Xenografts. Journal of Pharmacokinetics and Pharmacodynamics. 32(1). 65–83. 3 indexed citations
20.
Melewar, T.C. & John M. Harrold. (2000). The Role of Corporate Identity in Merger and Acquisition Activity. Journal of General Management. 26(2). 17–31. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Meille Breakdown of academic impact, for papers by Fumi Kinose Breakdown of academic impact, for papers by Rachel M. Webster Breakdown of academic impact, for papers by Sophie Callies Breakdown of academic impact, for papers by Charlene Kay Breakdown of academic impact, for papers by Anja Henningsson Breakdown of academic impact, for papers by Brent M. Kuenzi Breakdown of academic impact, for papers by Stefania Crucitta Breakdown of academic impact, for papers by Abhik Mukherjee Breakdown of academic impact, for papers by Theresa A. Mays
Rankless by CCL
2026